Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Advanced Gastric and…
T-DXd offers a targeted treatment option for HER2-positive advanced gastric cancers, with clinical evidence guiding patient selection and toxicity management strategies.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Management of Soft Tissue and Visceral Leiomyosarcomas.
Improved understanding of leiomyosarcoma's heterogeneity helps clinicians tailor management approaches and potentially reduce the substantial morbidity this rare cancer causes.
Standard additionTertiary lymphoid structures in pancreatic cancer
Identifying tertiary lymphoid structures in pancreatic cancer opens new avenues for enhancing immunotherapy effectiveness in this notoriously resistant tumor.
Standard additionSecond Transplantation for Relapsed Hematologic Malignancies After…
Second transplantation offers a potential path forward for patients who relapse after their first stem cell transplant, addressing a major clinical challenge.
Standard additionB-cell precursor acute lymphoblastic leukaemia
Ongoing research into B-cell ALL's biology continues improving survival rates for children with this most common pediatric cancer.